Fig. 3From: Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysisIncidence rates of the select immune-related adverse events of nivolumab plus ipilimumab. AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline phosphatase; GGT, γ-glutamyltransferaseBack to article page